Infinity Bio Partners with Austrian Institute of Technology to Deliver Antibody Reactome Profiling Across Europe
Infinity Bio, Inc., a pioneering leader in advanced immune system analysis, has announced a strategic partnership with the Austrian Institute of Technology (AIT), one of Europe’s foremost applied research centers. The collaboration aims to introduce Infinity Bio’s proprietary antibody reactome profiling platform to researchers across Europe, providing unprecedented resolution in mapping immune responses and accelerating biomarker discovery in a wide range of medical fields.
By integrating Infinity Bio’s MIPSA (Molecular Indexing of Proteins by Self-Assembly) technology with AIT’s established immunomics pipeline and extensive clinical infrastructure, the partnership will create a robust ecosystem for translational research. This combined approach will empower European scientists to investigate immune system behavior in ways not previously possible—spanning disciplines such as immunology, virology, autoimmune disease research, allergy science, and environmental immunology.
The Core of the Collaboration: MIPSA Technology Meets European Research
Infinity Bio’s MIPSA platform is considered a major leap forward in immune profiling technology. Unlike traditional antibody detection methods that are often limited to predefined antigen sets, MIPSA allows for unmatched breadth and resolution in identifying the full range of molecular targets of immune responses.
The technology enables high-throughput, comprehensive mapping of antibody reactivity, combining full-length protein and peptide libraries to cover a vast antigen space. This makes it possible to pinpoint the precise antigens—whether viral, human, or environmental—that an immune system has encountered or is currently responding to.
Infinity Bio’s antigen panel catalog reflects the versatility of this platform:
- VirSIGHT – Designed for the detection of antibodies against all known human viruses. This panel is valuable for infectious disease surveillance, vaccine research, and understanding viral immune histories.
- HuSIGHT – Focused on mapping antibodies to self-proteins, enabling advanced research in autoimmune disorders and uncovering potential triggers of immune dysregulation.
- EnviroSIGHT – Targets environmental antigens, including allergens, microbial proteins, and non-viral agents. This panel supports research in allergy diagnostics, environmental exposure studies, and microbiome-immune system interactions.
All three panels can be assessed in a single test, offering a unique level of comprehensiveness and efficiency.
Strategic Significance of the Partnership
The Austrian Institute of Technology has long been recognized for its leadership in translational science, bridging the gap between laboratory research and real-world medical applications. By joining forces with AIT, Infinity Bio gains a strong foothold in Europe’s research ecosystem while enabling European scientists to benefit from one of the world’s most advanced antibody profiling systems.
Ben Larman, Infinity Bio’s Co-founder and Chief Scientific Officer, emphasized the importance of this step:
“We are incredibly proud to partner with the prestigious Austrian Institute of Technology to expand access to our antibody reactome profiling services across Europe. AIT’s deep roots in translational science and innovation make them an ideal collaborator as we work to accelerate biomedical discovery and enable new breakthroughs in immunology research.”
For Infinity Bio, this partnership not only expands its geographical reach but also aligns with its mission to democratize access to sophisticated immune system analysis tools that can drive discoveries in both fundamental science and clinical applications.
Expanding Access to Advanced Antibody Profiling in Europe
The partnership ensures that European researchers will have direct and streamlined access to Infinity Bio’s MIPSA-based assays. While coordination and sample collection will take place through AIT’s Vienna-based facilities, the specialized analysis will be conducted at Infinity Bio’s headquarters in Baltimore, Maryland, USA. This model allows European institutions to benefit from state-of-the-art processing while leveraging AIT’s local expertise and logistical support.
Katy Saliba, Infinity Bio’s Director of Scientific Development, described the collaboration as a milestone in the global expansion of MIPSA technology:
“By partnering with AIT, we are expanding access to the most advanced antibody profiling platform available. This collaboration brings our MIPSA-based assays into the hands of European researchers, empowering them to generate deeper, more meaningful data in immunology and precision medicine. As someone deeply committed to advancing translational science, I am excited about the discoveries this partnership will catalyze.”
The combined infrastructure will enable faster turnaround times for European research projects, reduce logistical barriers, and ensure compliance with local sample handling and data regulations.
AIT’s Role: Bridging Clinical Research and Advanced Immunomics
AIT’s Molecular Diagnostics team is at the core of this collaboration. With over 20 years of experience in translational diagnostics, biomarker discovery, and assay development, AIT has cultivated a reputation for integrating cutting-edge tools into high-impact research projects.
In antibody profiling specifically, AIT’s proprietary immunomics pipeline is designed to analyze complex immune data and translate it into actionable biomedical insights. By integrating Infinity Bio’s MIPSA technology into this pipeline, the institute gains the ability to interrogate immune system responses on an unprecedented scale.
Dr. Andreas Weinhaeusel, Deputy Head of Molecular Diagnostics at AIT, explained:
“This collaboration enables us to offer the European research community access to one of the most advanced antibody profiling platforms currently available. By integrating Infinity Bio’s MIPSA technology with AIT’s immunomics pipeline and clinical network, we are advancing our mission to accelerate biomarker discovery and enable more precise, immune-informed medicine across Europe.”
This integration is expected to have wide-ranging implications—from improving early disease detection to supporting personalized medicine initiatives where immune signatures can guide therapeutic choices.
Applications Across Multiple Research Fields
The implications of bringing Infinity Bio’s MIPSA technology to Europe are far-reaching:
- Infectious Disease Research – The ability to map antibody responses to all known human viruses can inform vaccine development, epidemiological studies, and post-infection immunity assessments.
- Autoimmune Disease Investigation – HuSIGHT’s mapping of antibodies to self-proteins could reveal new autoantigens and pathways involved in conditions such as lupus, multiple sclerosis, and rheumatoid arthritis.
- Allergy and Environmental Exposure Studies – EnviroSIGHT’s comprehensive detection of allergens and microbial proteins will support the development of more precise allergy diagnostics and environmental health assessments.
- Oncology and Immunotherapy – Advanced immune profiling can help identify antibody responses related to tumor antigens, aiding in the design of cancer immunotherapies.
- Long COVID and Post-Viral Syndromes – Broad-spectrum viral antibody mapping could shed light on the immune mechanisms driving persistent symptoms after acute infections.
Elevating Precision Medicine in Europe
One of the most promising outcomes of the partnership is its potential to fuel precision medicine initiatives. By enabling comprehensive immune profiling, clinicians and researchers can develop more immune-informed diagnostic criteria, stratify patients for targeted therapies, and monitor immune responses during treatment.
AIT’s expertise in multi-omics approaches—combining genomics, proteomics, metabolomics, and now advanced immunomics—positions it as a hub for integrating diverse biological datasets into unified patient profiles.
For example, in cancer care, pairing MIPSA data with genomic mutation profiles could reveal tumor-specific immune responses that inform personalized vaccine development or immunotherapy selection. Similarly, in infectious diseases, understanding a patient’s complete antibody landscape could help predict susceptibility to future infections or responses to booster vaccines.
Strengthening Europe’s Biomedical Research Capacity
The collaboration also has a broader strategic impact: strengthening Europe’s biomedical research infrastructure. By granting European institutions access to a technology that was previously less available in the region, the partnership reduces dependence on overseas capabilities and fosters local expertise in high-resolution immune system analysis.
Given the rising importance of immune profiling in public health decision-making—illustrated most recently during the COVID-19 pandemic—having on-continent access to cutting-edge assays could enhance Europe’s ability to respond to emerging health threats more rapidly and effectively.
Both Infinity Bio and AIT anticipate that this partnership will act as a catalyst for a new wave of immune system research in Europe. Pilot projects are expected to begin in the coming months, focusing on priority areas such as autoimmune diagnostics, allergy biomarker discovery, and post-viral immune response mapping.
In the longer term, the partners plan to expand the scope of available antigen panels, incorporate novel bioinformatics tools for data interpretation, and explore collaborative grant opportunities within the European Union research framework.
The partnership between Infinity Bio, Inc. and the Austrian Institute of Technology represents a significant advancement for European biomedical research. By merging Infinity Bio’s MIPSA technology with AIT’s deep expertise in translational diagnostics, the collaboration offers a powerful new tool for understanding the immune system in unprecedented detail.
For researchers, clinicians, and public health professionals across Europe, the implications are clear: more comprehensive immune data, faster access to advanced assays, and a stronger foundation for innovations in diagnostics, therapeutics, and preventive medicine.
As Dr. Weinhaeusel of AIT noted, this is more than a technology integration—it is a step toward redefining immune system research in Europe and enabling a future where precision medicine is informed by the most detailed antibody profiling available.
Infinity Bio, Inc. is a technology company that provides detailed insights into the immune system using its proprietary antibody reactome profiling platform. The company’s core technology, MIPSA, is used to comprehensively analyze the antibody reactome, revealing the targets of individual immune responses against all known human viruses, human proteins (autoimmunity), and environmental antigens (including allergens, non-viral and microbial proteins). Developed at Johns Hopkins University in the Laboratory of Precision Immunology, MIPSA builds on decades of work in genomics, proteomics, immunology, and bioinformatics. Infinity Bio’s assays are engineered to enable best-in-class quality, data accuracy, turnaround times and cost-efficiency. For more information, visit www.infinitybio.com.
The Austrian Institute of Technology (AIT) is Austria’s largest applied research institute and a key player in diagnostic innovation. Within its Molecular Diagnostics unit, AIT specializes in non- and minimally invasive diagnostics, biomarker research, bioinformatics, biosensor development, and point-of-care systems. With a comprehensive systems approach and strong translational capabilities, AIT enables industrial and clinical partners to develop and implement next-generation diagnostic solutions that improve patient outcomes and drive precision medicine. For more information, visit https://molecular-diagnostics.ait.ac.at.
